(HealthDay)—For patients with heart failure due to light-chain amyloidosis (AL), three-drug therapy with bortezomib, dexamethasone, and an alkylating agent (BDex+AA) is associated with improved survival, according to a ...
Jun 21, 2016
0
34
A cocktail of three specific genes can reprogram cells in the scars caused by heart attacks into functioning muscle cells, and the addition of a gene that stimulates the growth of blood vessels enhances that effect, said ...
Jan 4, 2013
0
0
Using artificial intelligence (AI) to analyze specialized brain MRI scans of adolescents with and without attention-deficit/hyperactivity disorder (ADHD), researchers have found significant differences in nine brain white ...
Nov 29, 2023
0
0
Heart failure patients who live in communities affected by fracking are at increased risk for hospitalization, according to a study published in the Journal of the American College of Cardiology today. The study looked at ...
Dec 7, 2020
1
17
A new study found that using a patient's own bone marrow cells may help repair damaged areas of the heart caused by heart failure, according to research presented today at the American College of Cardiology's 61st Annual ...
Mar 26, 2012
0
0
The percutaneous catheter-based treatment of mitral regurgitation with the MitraClip system improves symptoms and cardiac function at one-year, according to results of a prospective observational study presented here today ...
Aug 27, 2012
0
0
Stem cell therapy helped to reduce the number of heart attacks, strokes and death among people with chronic, high-risk, NYHA class II or III heart failure with reduced ejection fraction (HFrEF), especially among those who ...
Nov 15, 2021
0
69
Women with chronic heart failure survive longer than their male counterparts, according to a large analysis of studies comprising data on more than 40,000 subjects. The analysis represents the largest assessment of gender ...
Mar 8, 2012
0
0
Empagliflozin reduces the risk of a composite of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction (HFpEF) with or without diabetes. That's the finding ...
Aug 27, 2021
0
176
Approval for Jardiance (empagliflozin) has been expanded to reduce the risk for cardiovascular death and hospitalization for heart failure in adults, the U.S. Food and Drug Administration announced Thursday.
Mar 1, 2022
0
18
